Solve Therapeutics rakes in $120M for two mystery ADCsnews2025-11-17T13:03:19+00:00November 17th, 2025|Endpoints News|
Artios Pharma raises $115M for DNA damage response programsnews2025-11-17T13:00:52+00:00November 17th, 2025|Endpoints News|
Nuvalent shares Phase 1/2 data for ALK inhibitor that could battle with Pfizer’s Lorbrenanews2025-11-17T11:50:47+00:00November 17th, 2025|Endpoints News|
Lilly makes up to $2.6B pact with South Korean biotech ABL Bionews2025-11-17T10:28:16+00:00November 17th, 2025|Endpoints News|
Genmab cans another ADC from ProfoundBio deal in area of J&J’s Ambrx buyoutnews2025-11-17T10:04:19+00:00November 17th, 2025|Endpoints News|
Sofinnova secures $750M for eleventh fund focused on drugmakers nearing the clinicnews2025-11-17T01:01:20+00:00November 17th, 2025|Endpoints News|
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and morenews2025-11-15T11:00:13+00:00November 15th, 2025|Endpoints News|
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing studynews2025-11-14T20:48:04+00:00November 14th, 2025|Endpoints News|
Onshoring and data ‘fidelity’: What FDA wants from generic drug user fee talksnews2025-11-14T20:47:05+00:00November 14th, 2025|Endpoints News|
CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatmentnews2025-11-14T19:42:51+00:00November 14th, 2025|Endpoints News|
